Tag Directory / NEUROSCIENCE     showing 1–1 of 1   RSS

for: Saturday, August 01, 2026



FDA approves Simtriyo for treating ADHD in children and adults

medicalxpress - The U.S. Food and Drug Administration has approved Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children 6 years and older weighing ≥20 kg.

AI Summary: The FDA granted approval for Simtriyo to treat attention‑deficit/hyperactivity disorder in children and adults, adding a new prescription option to the ADHD toolkit. Regulators highlighted efficacy and safety data supporting the decision; clinicians and patients will now weigh the drug’s profile against existing therapies as rollout and coverage decisions play out.

ADHD diagnoses and prescriptions have increased globally across all age groups, our review shows

21 days / medicalxpress

F.D.A. Approves Moderna’s mRNA Flu Vaccine

24 days / nytimes / Christina Jewett

Study identifies link between caregiver-child relationship, ADHD symptoms

27 days / medicalxpress

FDA approves Simtriyo for treating ADHD in children and adults

4 wks / medicalxpress

FDA approves new ADHD medication: 4 things to know

4 wks / beckershospitalreview / Ella Ruder



Back to Top


NEUROSCIENCE Heatmap

90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.


StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Reproductive Health, Supplements, Digital Health, Alzheimer's disease and look for the RSS link.

Back to Top
↑

NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.